2020-4-30 18:30 |
U.S. stock markets are rallying after an inconclusive study on Gilead's remdesivir. The flimsy trial didn't even have a control group. The post The Stock Market Is Insane to Rally on Gilead’s Flimsy Remdesivir Study appeared first on CCN.com origin »
|
Coinspeaker Gilead Sciences Says It Will Meet Global Remdesivir Demand by October, GILD Stock Price Is RisingGilead has confirmed its capacities to produce Remdesivir in such volumes that will meet global demand.
Coinspeaker GILD Stock Lost 1% Yesterday, Gilead Starts Early-Stage Trial for Its Remdesivir DrugGilead Sciences (GILD) stock is slightly down despite the progress that the company made in testing of its remdesivir drug that can be used as the coronavirus treatment.
Coinspeaker Better Buy: Moderna (MRNA) vs Gilead Sciences (GILD)The coronavirus pandemic is raging and there's still no treatment or vaccine. Regardless, let's look at the stocks of two major biotech companies: Gilead Sciences and Moderna.
Coinspeaker Gilead (GILD) Stock Falls Nearly 4% Despite Positive Remdesivir Phase 3 Trial DataDespite the fact that the latest results of remdesivir trials are inspiring, Gilead (GILD) stock is down.
Coinspeaker Gilead (GILD) Stock Price Up Nearly 1% Now, CEO Confirms Over 50K Remdesivir Courses Ready50,000 units of Remdesivir are ready for shipment. The drug has passed initial trials and has been proven to be effective in the treatment of COVID-19.
Coinspeaker Gilead Sciences (GILD) Stock Down 0. 6% Now but Gained 10% in a Week, Will It Keep Rising?Gilead Sciences Inc (GILD) stock price is going northward these days, though today it is slightly down.